Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone

What Was Tested

This randomized controlled trial paper looks at Therapeutic nicotine (patch, non-peptide).

To evaluate concurrent administration of mecamylamine (nicotine antagonist) with nicotine skin patch treatment for smoking cessation.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

The subjects ranged in age from 20 to 40 years.

Mecamylamine treatment began 2 weeks before smoking cessation.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

This was a randomized, double-blind, placebo-controlled trial.

The primary outcome was continuous abstinence through 7 weeks after cessation (1 week after treatment), confirmed by expired air carbon monoxide measurements.

Secondary measures included point abstinence at 7 weeks, continuous abstinence at 6- and 12-month follow-up, and self-reported withdrawal symptoms.

What Was Measured

PubMed files the paper under topics including Administration, Cutaneous, Affect, Blood Pressure, Breath Tests, Carbon Monoxide, Heart Rate and Mecamylamine.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1994 (Clinical pharmacology and therapeutics), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.